Press release
Behcet's Disease Market Expected to Expand Significantly by 2034, Driven by Pipeline Innovation and Rising Disease Awareness DelveInsight
Explore the Behcet's Disease Market Outlook, Treatment Landscape, and Epidemiology: https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Key Highlights of the Behcet's Disease Market Report
• The Behcet's disease market was valued at approximately USD 140 million in 2023 and is anticipated to grow at a significant CAGR during the forecast period from 2020 to 2034.
• In August 2025, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to dusquetide, the active ingredient in Soligenix's investigational therapy SGX945, for the treatment of Behcet's disease.
• In July 2025, Soligenix reported positive findings from its Phase IIa clinical study evaluating SGX945 in Behcet's disease and announced plans to advance the program toward a placebo-controlled Phase IIb study following reformulation of the therapy.
• In March 2025, Soligenix highlighted upcoming milestones for its clinical pipeline, including anticipated data from its Phase II program evaluating SGX945 in Behcet's disease.
• In November 2024, Soligenix announced the initiation of patient enrollment in its Phase II clinical trial evaluating SGX945 (dusquetide) for Behcet's disease.
• According to DelveInsight's analysis, approximately 73,000 diagnosed prevalent cases of Behcet's syndrome were reported across the 7MM in 2023. The diagnosed patient population is expected to increase through 2034, supported by greater disease awareness and improved recognition and diagnosis.
• Among the EU4 and the UK, Italy accounted for the highest number of diagnosed prevalent cases in 2023, followed by Spain and France.
• The United States recorded approximately 20,000 diagnosed prevalent cases of Behcet's syndrome in 2023, with young adults representing the majority of diagnosed patients.
• Japan had the highest diagnosed prevalent population among the 7MM in 2023, with nearly 33,000 diagnosed cases.
• Key companies developing therapies for Behcet's disease include Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others.
• Leading therapies and pipeline candidates include SGX945, RAY121, dusquetide, filgotinib, Hemay005, apremilast, and others.
• Increasing disease awareness, expanding research activity, and the introduction of novel pipeline therapies are expected to contribute to changes in the Behcet's disease market dynamics during the forecast period.
Behcet's Disease Overview
Behcet's disease is a rare, chronic, multisystem inflammatory disorder characterized by recurrent episodes of inflammation that can affect multiple organs and tissues. Common manifestations may involve the mouth, eyes, skin, joints, blood vessels, and other organ systems.
The disease was first described by Turkish dermatologist Hulusi Behcet in 1937. Because of its broad range of clinical manifestations and variable disease course, timely diagnosis and effective long-term management remain important areas of clinical focus.
Get a Free Sample of the Behcet's Disease Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Behcet's Disease Epidemiology
The epidemiology section of the report provides historical, current, and forecasted estimates for Behcet's disease across the 7MM from 2020 to 2034. The analysis incorporates epidemiological studies, published literature, and expert perspectives to assess disease burden and patient population trends.
Behcet's Disease Epidemiology Segmentation
The report evaluates the Behcet's disease population across the following segments:
• Total diagnosed prevalent cases of Behcet's syndrome in the 7MM
• Diagnosed cases of Behcet's syndrome based on age of onset in the 7MM
• Clinical manifestations associated with Behcet's syndrome in the 7MM
• Total patients seeking treatment for Behcet's syndrome in the 7MM
Discover the Factors Driving Behcet's Disease Epidemiology Trends: https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Behcet's Disease Drug Uptake and Pipeline Development
The report provides a detailed assessment of drug uptake across the Behcet's disease therapeutic landscape. It evaluates the expected adoption of recently launched and emerging therapies, patient uptake, drug sales, and potential market share.
The therapeutic assessment also identifies candidates that may demonstrate rapid uptake and examines the factors that could influence their commercial performance.
In addition, the report reviews pipeline development activities, including clinical-stage therapies, collaborations, acquisitions, mergers, licensing agreements, patent-related developments, and other strategic activities shaping the future treatment landscape.
Behcet's Disease Therapies and Key Companies
• SGX945 Soligenix
• RAY121 Chugai Pharmaceutical
• Dusquetide Soligenix
• Filgotinib UMC Utrecht
• Hemay005 Ganzhou Hemay Pharmaceutical
• Apremilast Amgen
Explore the Behcet's Disease Treatment Landscape and Emerging Therapies: https://www.delveinsight.com/sample-request/behcets-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr
Behcet's Disease Market Strengths
• Continued research into the molecular mechanisms and pathogenesis of Behcet's disease is improving understanding of the condition and its potential therapeutic targets.
• Research identifying similarities between Behcet's syndrome and other autoimmune and inflammatory disorders may support the discovery of important inflammatory mediators and novel treatment approaches.
• Growing scientific understanding may contribute to the development of more targeted therapeutic strategies.
Behcet's Disease Market Opportunities
• Significant opportunities exist for therapies capable of rapidly controlling inflammatory attacks and preventing recurrence while reducing the risk of irreversible organ damage.
• Increasing awareness among healthcare professionals, patients, and caregivers may improve disease recognition and diagnosis.
• Growing understanding of disease biology and unmet treatment needs could encourage additional research and development activity.
• The expanding pipeline of investigational therapies may provide new treatment options for patients with limited therapeutic choices.
Scope of the Behcet's Disease Market Report
• Study Period: 2020-2034
• Geography: 7MM - United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan
• Key Companies: Soligenix, Chugai Pharmaceutical, UMC Utrecht, Ganzhou Hemay Pharmaceutical, Amgen, and others
• Key Therapies: SGX945, RAY121, dusquetide, filgotinib, Hemay005, apremilast, and others
• Therapeutic Assessment: Current marketed and emerging Behcet's disease therapies
• Market Dynamics: Key market drivers and barriers
• Competitive Intelligence: SWOT analysis, PESTLE analysis, Porter's Five Forces, BCG Matrix, and market entry strategies
• Unmet Needs: Assessment of existing treatment gaps and future opportunities
• Expert Perspectives: KOL and analyst insights
• Market Access: Market access and reimbursement analysis
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Contact No.: +14699457679
Address: 304 S. Jones Blvd #2432, Las Vegas, Nevada 89107, United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a healthcare business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market intelligence, epidemiology, competitive intelligence, and consulting solutions to pharmaceutical and biotechnology organizations.
Through its healthcare consulting services, DelveInsight supports clients in evaluating market opportunities, understanding competitive landscapes, identifying unmet needs, and developing practical strategies to accelerate business growth and address complex commercial challenges.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Behcet's Disease Market Expected to Expand Significantly by 2034, Driven by Pipeline Innovation and Rising Disease Awareness DelveInsight here
News-ID: 4609446 • Views: …
More Releases from Delveinsight Business Research LLP
The Global Brain Monitoring Devices Market Size is projected to grow at a CAGR o …
The Brain Monitoring Devices market was valued at USD 5.89 billion in 2024 and is projected to reach USD 9.13 billion by 2032. Growth is driven by increasing instances of neurological disorders such as multiple sclerosis, epilepsy, and dementia, coupled with increasing awareness of these disorders and rising product developmental activities.
DelveInsight's Brain Monitoring Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Brain Monitoring Devices…
The Global Neurovascular Devices Market Size is projected to grow at a CAGR of 8 …
The Neurovascular Devices market is estimated at USD 3,904.74 million in 2025 and is projected to reach USD 8,044.66 million by 2034. Growth is anchored in the rising prevalence of stroke, cerebral aneurysms, and other cerebrovascular diseases, alongside continuous technological advancement in minimally invasive devices.
DelveInsight's Neurovascular Devices Market Insights Report 2034 provides the current and forecast market analysis, individual leading Neurovascular Devices companies' market shares, challenges, Neurovascular Devices Market Drivers,…
The Global Peripheral Vascular Devices Market Size is projected to grow at a CAG …
The Peripheral Vascular Devices market is estimated at USD 9,853.30 million in 2024 and is projected to reach USD 15,544.32 million by 2032. Growth is anchored in the rising burden of Peripheral Artery Disease (PAD) and vascular disorders, increasing preference for minimally invasive procedures, and continuous technological advancement in product design.
DelveInsight's Peripheral Vascular Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Peripheral Vascular Devices…
Erectile Dysfunction Market Expected to Witness Significant Growth by 2034, Driv …
DelveInsight Business Research LLP has published its latest report, "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast - 2034," providing a comprehensive evaluation of the erectile dysfunction (ED) landscape across the seven major markets (7MM), including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The report examines historical and forecasted epidemiology, treatment patterns, emerging therapies, drug uptake, market dynamics, and the competitive landscape through 2034.
Explore…
More Releases for Behcet
Behçet's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Comp …
DelveInsight's, "Behçet's Disease Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behçet's Disease pipeline landscape. It covers Behçet's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers Behçet's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Behçet's Disease Pipeline…
Behcet disease drug Market Comprehensive Insight by Growth Rate, Industry Status …
Behcet disease drug Market is anticipated to grow at a considerable CAGR during the forecast period. The use of biosimilars has increased in recent times. It will also rise in the future as biosimilars serve as a low-cost, easy option. Biosimilars are medicines that are close to biological drugs. They have the same characteristics, structure, and composition as biological drugs. Biologic drugs are those drugs that are made from several…
Rising Demand for Behcet disease drug Market Key Players, Growth Analysis during …
The global Behcet disease drug market is anticipated to grow at a considerable CAGR during the forecast period. The use of biosimilars has increased in recent times. It will also rise in the future as biosimilars serve as a low-cost, easy option. Biosimilars are medicines that are close to biological drugs. They have the same characteristics, structure, and composition as biological drugs. Biologic drugs are those drugs that are made…
Behcet Disease Drug Market is Projected to Expand at a Steady CAGR over the Fore …
This in-depth Behcet Disease Drug market report makes determining the market's pulse a breeze. All competition-related statistics and market size for key regions such as North America, Europe, Latin America, Asia Pacific, and the Middle East can be found here. It also gives essential industry information along with the status of the rivals in the market. Accurate results are also gathered in this market study. It determines the specific needs…
Behcet Disease Drug Market 2021 Boosting the Growth, Dynamics Trends, Efficienci …
The report titled “Global Behcet Disease Drug MARKET “is one of the most comprehensive and important additions to market research studies. It offers detailed research and analysis of key aspects of the Behcet Disease Drug market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Behcet Disease Drug market. Market Participants can use…
Behcet Disease - Pipeline Review, H2 2018: Otezla Demonstrated Favorable Results …
Denoted by frequent and painful ulcers of the mouth and genitals, Behcet disease is a type of inflammatory disease such as immune mediated inflammatory disease triggered by abnormal immune response and often leading to mortality. Significant rise in occurrences of such autoimmune disorders has necessitated substantial advancement in Behcet disease therapeutics. To understand ongoing advancement in therapeutics development and their reciprocal implications, Market Research Hub (MRH) has collated a new…
